Surrogate markers of bowel inflammation are increasingly being recognized as important , not only as markers of disease activity in inflammatory bowel disease (IBD) but also to differentiate irritable bowel syndrome (IBS) from IBD.
In this study we investigated EDTA-plasma of 68 patients with gastrointestinal cancer , 22 patients with inflammatory bowel disease (IBD) and 60 healthy controls.
The present study was designed to evaluate the use of a new tumor marker , tumor M (2) - PK , in discriminating gastrointestinal cancer patients from healthy controls , and to compare with the reference tumor markers CEA and CA72-4.
Proliferating cells and tumor cells maintain a high glycolytic rate even under aerobic conditions.
Glutamine in a high glucose (HG) environment increased cell proliferation in a dose-dependent manner.